2019 年第 1 期 第 14 卷

单独应用血管紧张素转换酶抑制剂或血管紧张素Ⅱ受体拮抗剂治疗特发性膜性肾病患者的预后及其影响因素分析

Prognostic factors of idiopathic membranous nephropathy treated with angiotensin converting enzyme inhibitor/angiotensin Ⅱ receptor blocker 

作者：孙彬彬张蓓茹边晓慧赵自霞于锐张永哲王艳秋

英文作者：

单位：110004沈阳，中国医科大学附属盛京医院肾内科

英文单位：

关键词：特发性膜性肾病；血管紧张素转换酶抑制剂；血管紧张素Ⅱ受体拮抗剂

英文关键词：

• 摘要：

• 【摘要】目的    探讨单独应用血管紧张素转换酶抑制剂（ACEI）或血管紧张素Ⅱ受体拮抗剂（ARB）治疗的特发性膜性肾病（IMN）患者的预后及影响因素。方法    选取2011年12月至2016年12月于中国医科大学附属盛京医院肾内科经肾穿刺活检诊断为IMN患者85例，均只接受ACEI或ARB治疗，完全缓解、部分缓解者纳入缓解组，开始接受糖皮质激素和/或免疫抑制剂治疗者纳入未缓解组，比较2组患者基本资料、生化指标和肾脏病理结果，评估IMN患者单独应用ACEI/ARB治疗的预后影响因素。结果    缓解组46例，其中完全缓解29例，部分缓解17例；未缓解组39例。缓解组＜60岁患者比例、eGFR水平高于未缓解组［89.1%(41/46)比66.7%(26/39)，（138±29）ml/(min·1.73 m2）比（120±28）ml/(min·1.73 m2）］，未缓解组合并糖尿病比例、血清胱抑素C水平高于缓解组［20.5%(8/39)比2.2%(1/46)，（1.04±0.32）mg/L比（0.91±0.17）mg/L］，未缓解组的间质炎性细胞浸润评分高于缓解组，补体C3沉积程度低于缓解组，差异均有统计学意义（均P＜0.05）。Logistic多因素回归分析结果提示，具有糖尿病病史、血清胱抑素C水平升高是影响IMN患者预后的独立危险因素（比值比=408.862、46.973,95%置信区间:4.447~37 590.022、3.091~713.836,均P＜0.01）。结论    单独ACEI/ARB治疗可使部分IMN患者达到缓解，既往有糖尿病病史以及高胱抑素C血症可能影响患者预后，应根据患者的情况选择个体化的治疗方案。

• 【Abstract】Objective    To investigate the prognosis and related factors of idiopathic membranous nephropathy (IMN) treated with angiotensin converting enzyme inhibitor/angiotensin Ⅱ receptor blocker(ACEI/ARB). Methods    From December 2011 to December 2016, 85 IMN patients diagnosed by renal biopsy in Shengjing Hospital of China Medical University were enrolled. All patients were treated with ACEI/ARB alone. According to the therapeutic response, they were divided into remission group and no remission group; the no remission group was treated with glucocorticoids and/or immunosuppressants subsequently. Basic information, biochemical indexes and pathological results were compared between groups. Prognostic factors of IMN patients treated by ACEI/ARB were analyzed. Results    There were 46 patients in the remission group(29 complete remission, 17 partial remission) and 39 patients in the no remission group. Proportion of patients under 60 years old and estimated glomerular filtration rate in the remission group were higher than those in the no remission group［89.1%(41/46) vs 66.7%(26/39), （138±29）ml/(min·1.73 m2） vs （120±28）ml/(min·1.73 m2）］. Proportion of patients with diabetes and level of serum cystatin C in the no remission group were higher than those in the remission group［20.5%(8/39) vs 2.2%(1/46), （1.04±0.32）mg/L vs （0.91±0.17）mg/L］. The no remission group had higher interstitial inflammatory cell infiltration score and lower complement C3 sedimentation degree（all P＜0.05）. Logistic multivariate regression analysis showed that diabetes history and high serum cystatin C level were independent risk factors of the prognosis of IMN（dds ratio=408.862, 46.973; 95% confidence interval: 4.447-37 590.022, 3.091-713.836; P＜0.01）. Conclusions    Monotherapy with ACEI/ARB can relieve IMN in some patients. Diabetes history and high serum cystatin C level may have adverse affect the therapeutic response of IMN.